

Date 14/07/2025
Your Ref
Our Ref 10254

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – MELANOMA

I write in response to your request for information in relation to melanoma prescribing.

Question:

1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib
- Dabrafenib
- Dabrafenib + Trametinib
- Dacarbazine
- Denosumab
- Encorafenib + Binimetinib
- Ipilimumab monotherapy
- Ipilimumab + Nivolumab
- Nivolumab monotherapy
- Nivolumab + Relatlimab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib + Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

Answer:

- Cobimetinib 0
- Dabrafenib 5 or fewer
- Dabrafenib + Trametinib 16
- Dacarbazine 0
- Denosumab 0
- Encorafenib + Binimetinib 25
- Ipilimumab monotherapy 5 or fewer

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
*Lothian NHS Board is the common
name of Lothian Health Board*

- Ipilimumab + Nivolumab 5 or fewer
- Nivolumab monotherapy 8
- Nivolumab + Relatlimab 5 or fewer
- Pembrolizumab 33
- Trametinib 0
- Vemurafenib 0
- Vemurafenib + Cobimetinib 0
- Other active systemic anti-cancer therapy 5 or fewer
- Palliative care only 34

Question:

2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- Ipilimumab monotherapy
- Ipilimumab + Nivolumab
- Nivolumab monotherapy
- Nivolumab + Relatlimab
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy
- Palliative care only

Answer:

- Ipilimumab monotherapy 5 or fewer
- Ipilimumab + Nivolumab 5 or fewer
- Nivolumab monotherapy 7
- Nivolumab + Relatlimab 5 or fewer
- Pembrolizumab 17
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) 38
- Other active systemic anti-cancer therapy 5 or fewer
- Palliative care only 34

Question:

3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- Ipilimumab (monotherapy)
- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)
- Nivolumab AND Relatlimab

- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Answer:

- Ipilimumab (monotherapy) 5 or fewer
- Nivolumab (monotherapy) 0
- Nivolumab AND Ipilimumab (combination) 5 or fewer
- Nivolumab AND Relatlimab 5 or fewer
- Pembrolizumab 10
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib/Vemurafenib /Vemurafenib AND Cobimetinib) 9
- Other active systemic anti-cancer therapy 0

Question:

4. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

Answer:

Full Title	Recruited
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA	5 or fewer

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at

www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive